DiaMedica Therapeutics (DMAC) EBITDA Margin (2018)
DiaMedica Therapeutics (DMAC) posted quarterly EBITDA Margin of 297.4% for Q3 2018.
DiaMedica Therapeutics (DMAC) EBITDA Margin (2018) Analysis & Trends
DiaMedica Therapeutics' EBITDA Margin history runs 1 years deep, the most recent figure standing at 297.4% for Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | DiaMedica Therapeutics | 360.22 Mn | 360.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | -297.40% |